A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Short name ATTAIN-CN

NCTNCT07790861Other id27942Other idJ2A-GH-GZVC

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Not yet recruiting
Phase: Phase 3
Enrollment: 192 participants (estimated)
Sponsor: Eli Lilly and Company · Industry
Design: Randomized · Double masking
Countries: 1 country
China
Start: Dec 2026 (estimated)
Primary completion: Mar 2028 (estimated)
Completion: Mar 2028 (estimated)
First posted: 27 Aug 2026
Last update posted: 13 Oct 2026
Conditions: Obesity · Overweight

Timeline

1 trial · 1 not yet recruiting

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2026202720282029

Ph 3
ATTAIN-CN
NCT07790861
est. Dec 2026 to est. Mar 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Interventions

OrforglipronDrug
PlaceboDrug

Arms2

Experimental
Orforglipron
Participants will receive orforglipron orally.
Placebo comparator
Placebo
Participants will receive placebo orally.

Primary outcomes1

Outcomes the sponsor listed as primary.

Mean Percent Change From Baseline in Body Weight
Time frame · Baseline, Week 48

Secondary outcomes(10)

Mean Change from Baseline in Waist Circumference
Time frame · Baseline, Week 48
Mean Change from Baseline in Body Mass Index (BMI)
Time frame · Baseline, Week 48
Mean Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame · Baseline, Week 48
Mean Change from Baseline in Fasting Glucose
Time frame · Baseline, Week 48
Mean Percent Change from Baseline in Fasting Insulin
Time frame · Baseline, Week 48
Mean Change from Baseline in Systolic Blood Pressure (SBP)
Time frame · Baseline, Week 48
Mean Change from Baseline in Diastolic Blood Pressure (DBP)
Time frame · Baseline, Week 48
Mean Percent Change from Baseline in Fasting non-HDL Cholesterol
Time frame · Baseline, Week 48
Mean Percent Change from Baseline in Fasting Triglycerides
Time frame · Baseline, Week 48
Mean Change from Baseline in Short Form Version 2 (SF-36v2) Acute Form Domain Scores
Time frame · Baseline, Week 48

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex: All
Age: from 18 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and \<30 kg/m2 or ≥24.0 kg/m2 and \<28 kg/m2, and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea * Fatty liver * cardiovascular disease * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * Have a self-reported change in body weight \>5 kg within 90 days prior to screening * Had chronic or acute pancreatitis any time prior to screening * Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome

PepBank is a research reference. Talk to a doctor before you use any peptide.